This session presents mechanistic studies of hepatic immune regulation, covering macrophage polarization, T cell responses in transplantation and cirrhosis, and circadian regulation of ischemia-reperfusion injury.

This session explores the interplay between frailty, metabolic health, and long-term outcomes across the liver transplant continuum. Presentations characterize frailty and cardiovascular-kidney-metabolic risk from candidacy through post-transplant recovery, and examine emerging therapeutic strategies—including GLP-1 receptor agonists—to improve survival and reduce cardiometabolic complications. Together, these studies highlight opportunities to refine risk stratification and intervene on modifiable factors that shape recipient outcomes.

This session examines the structural, geographic, and clinical factors that shape who gains access to liver transplantation and how organs are allocated. Presentations address disparities across the transplant continuum—from waitlist mortality risk and MELD-based allocation to the influence of public perception on donation—highlighting opportunities for more equitable practice. Together, these studies offer evidence to inform allocation reform and reduce inequities in transplant access.

This session presents population-level data on MASLD prevalence, fibrosis progression, and outcomes, including AI-based analyses of NHANES data and community screening cohorts.

This session examines pharmacologic (GLP-1 agonists, resmetirom) and lifestyle-based interventions for MASH/MASLD across adult and pediatric populations, including transplant recipients.

This session reviews non-invasive diagnostic and monitoring tools for MASH, including novel imaging, cfDNA methylation, and composite scores for identifying fibrosis and disease progression.

This session covers advances in inherited metabolic liver diseases — Wilson disease, alpha-1 antitrypsin deficiency, and acute hepatic porphyria — including natural history data and emerging targeted therapies.

This session presents genetic and mechanistic insights into biliary atresia and pediatric cholangiopathies, alongside emerging therapies and outcomes following Kasai portoenterostomy.

The management of portal hypertension is rapidly evolving from static staging paradigms toward dynamic, individualized risk assessment, evolving guidelines and deeper understanding of treatment response and disease regression. Novel non-invasive tools, machine-learning algorithms, and longitudinal measurements now allow clinicians to diagnose clinically significant portal hypertension (CSPH), predict decompensation, and monitor treatment response without reliance on invasive hepatic venous pressure gradient measurements. This session will highlight contemporary data validating Baveno VIII criteria, emerging artificial intelligence approaches, perioperative management in advanced liver disease, and the growing role of serial non-invasive testing in identifying patients most likely to benefit from targeted therapies.
 

This session explores microbiome-liver interactions across disease states, including virome and metagenomic signatures in PSC, gut-derived metabolites in fibrosis, and microbiome-linked mechanisms in alcohol-related hepatitis.